TheraSkin Product Specifications

Download the files in the language of your choice
Instructions for Use
Product Specifications


Living Cell Skin Allograft

TheraSkin is an all-human, split-thickness skin allograft with living cells and retained endogenous growth factors, and a native extracellular matrix. TheraSkin can be vascularized by the recipient following transplantation to support development of granulation tissue, which aids in epithelialization to support wound closure.1-3

  • Retained Endogenous Growth Factors: Growth factors and cytokines naturally present in the donated tissue are retained in the donor’s extracellular matrix, to support angiogenesis.
  • Intact ECM: TheraSkin ECM provides a natural skin environment to enable a number a functions, including structural support, a substrate for cell movement, and direct interactions with the recipient cells to help facilitate and support healing.
  • Living Cells: Viable fibroblasts and keratinocytes, the living cells found within human skin, are critical to support healing of the patient’s damaged or diseased skin.
Clinical Application

A barrier membrane for chronic wounds including:

  • Diabetic Foot Ulcers
  • Venous Statis Ulcers
  • Pressure Ulcers
  • Dehisced Surgical Wounds
Frozen Description Sizing
3TS Meshed Sheet 0.69 x 0.69 in, 1.75 x 1.75 cm
100TSXS Meshed Sheet 1.00 x 1.00 in, 2.5 x 2.5 cm
101TSS Meshed Sheet 1.00 x 2.00 in, 2.5 x 5.1 cm
26TS Meshed Sheet 1.57 x 2.56 in, 4.0 x 6.5 cm
102TSL Meshed Sheet 2.00 x 3.00 in, 5.1 x 7.6 cm
103TSXL Meshed Sheet 3.00 x 6.00 in, 7.6 x 15.24 cm
104TSXLR Meshed Sheet 3.00 x 6.00 in, 7.6 x 15.24 cm
  1. Flood MS, Weeks B, Anaeme KO, et al. Treatment of deep full-thickness wounds containing exposed muscle, tendon, and/or bone using a bioactive human skin allograft: a large cohort case series. Wounds. 2020;32(6):164-73.
  2. Barbul A, Gurtner GC, Gordon H, Bakewell K, Carter MJ. Matched-cohort study comparing bioactive human split-thickness skin allograft plus standard of care to standard of care alone in the treatment of diabetic ulcers: A retrospective analysis across 470 institutions. Wound Repair Regen. 2020;28(1):81-9. doi:10.1111/wrr.12767.
  3. Gurtner GC, Garcia AD, Bakewell K, Alarcon JB. A retrospective matched-cohort study of 3994 lower extremity wounds of multiple etiologies across 644 institutions comparing a bioactive human skin allograft, TheraSkin, plus standard of care, to standard of care alone. Int Wound J. 2020;17(1):55-64. doi:10.1111/iwj.13231.